Compounds > azacitidine

azacitidine and Cystadenocarcinoma, Serous

azacitidine has been researched along with Cystadenocarcinoma, Serous in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (60.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bachman, KE; Baylin, SB; Brown, SM; Casero, RA; Dunworth, M; Foley, JR; Holbert, CE; Stone, ML; Travers, M; Wiehagen, KR; Zahnow, CA1
Chang, YM; Khabele, D; Kim, JW; Schreiber, SL; Shamji, AF; Stewart, ML; Tamayo, P; Wang, S; Wilson, AJ1
Kohno, T; Nishioka, M; Ochiai, K; Okamoto, A; Otsuka, A; Tanaka, T; Yanaihara, N; Yokota, J1
Chan, KY; Cheung, AN; Chiu, PM; Ip, P; Khoo, US; Ngan, HY; Shen, DH; Xue, WC1
Izutsu, N; Maesawa, C; Masuda, T; Oikawa, H; Shibazaki, M; Shoji, T; Sugiyama, T1

Other Studies

5 other study(ies) available for azacitidine and Cystadenocarcinoma, Serous

ArticleYear
DFMO and 5-Azacytidine Increase M1 Macrophages in the Tumor Microenvironment of Murine Ovarian Cancer.
    Cancer research, 2019, 07-01, Volume: 79, Issue:13

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cystadenocarcinoma, Serous; Disease Models, Animal; Eflornithine; Female; Immunity, Innate; Macrophages; Mice; Mice, Inbred C57BL; Ovarian Neoplasms; Polyamines; Tumor Cells, Cultured; Tumor Microenvironment

2019
KRAS Genomic Status Predicts the Sensitivity of Ovarian Cancer Cells to Decitabine.
    Cancer research, 2015, Jul-15, Volume: 75, Issue:14

    Topics: Animals; Azacitidine; Biomarkers, Tumor; Cystadenocarcinoma, Serous; Decitabine; Drug Resistance, Neoplasm; Female; Genes, ras; Humans; Mice; Mice, Nude; Mice, Transgenic; Mutation; Ovarian Neoplasms; Prognosis; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2015
Reduced expression of MYO18B, a candidate tumor-suppressor gene on chromosome arm 22q, in ovarian cancer.
    International journal of cancer, 2004, Oct-20, Volume: 112, Issue:1

    Topics: Azacitidine; Carcinoma, Endometrioid; Case-Control Studies; Chromosomes, Human, Pair 22; Cystadenocarcinoma, Mucinous; Cystadenocarcinoma, Serous; Decitabine; DNA Methylation; DNA Mutational Analysis; Female; Genes, Tumor Suppressor; Humans; Hydroxamic Acids; Mutation, Missense; Myosin Heavy Chains; Ovarian Neoplasms; Ovary; Promoter Regions, Genetic; Tumor Cells, Cultured

2004
Epigenetic and genetic alterations of p33ING1b in ovarian cancer.
    Carcinogenesis, 2005, Volume: 26, Issue:4

    Topics: Adenocarcinoma, Clear Cell; Antimetabolites, Antineoplastic; Azacitidine; Carcinoma, Endometrioid; Case-Control Studies; Cell Cycle Proteins; CpG Islands; Cystadenocarcinoma, Mucinous; Cystadenocarcinoma, Serous; Decitabine; DNA Methylation; DNA-Binding Proteins; Female; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Immunoenzyme Techniques; Inhibitor of Growth Protein 1; Intracellular Signaling Peptides and Proteins; Loss of Heterozygosity; Mutation; Nuclear Proteins; Ovarian Neoplasms; Ovary; Promoter Regions, Genetic; Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Tumor Suppressor Proteins

2005
Epigenetic modification is involved in aberrant expression of class III beta-tubulin, TUBB3, in ovarian cancer cells.
    International journal of oncology, 2008, Volume: 32, Issue:6

    Topics: Azacitidine; CpG Islands; Cystadenocarcinoma, Serous; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Ovarian Neoplasms; Polymerase Chain Reaction; Promoter Regions, Genetic; RNA, Messenger; Tubulin; Tumor Cells, Cultured

2008